Conventional allogeneic transplantation (allo-BMT) saves lives, but carries high complications, burden on quality of life and limitations on survival.
Next-generation life-saving therapies (engineered grafts, CAR T) cannot be imported due to fresh cell logistics restrictions, are expensive, and are not accessible to patients.
Nexus Biologic, through the National Institute of Advanced Cell Therapy, is building the first integrated industrial platform for cell therapies in Latin America, based in Chile.